Purple Biotech Ltd (PPBT)Healthcare | Biotechnology | Rehovot, Israel | NasdaqCM
1.22 USD
-0.01
(-0.813%) ⇩
(Oct. 16, 2026, 12:19 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:19 a.m. EDT
The investment case for Purple Biotech is effectively zero, driven by a catastrophic multi-year decline and deteriorating fundamentals. The stock has lost 99.9% of its value over the last nine years, with four consecutive years of negative returns, signaling a structural implosion rather than a temporary setback. Fundamentally, the company is bleeding cash with negative free cash flow and a return on equity of -111%, while trading at a fraction of its book value due to the market's complete loss of faith in its prospects. The recent news of a 92% surge on a drug breakthrough is likely a 'dead cat bounce' or a one-off event that failed to reverse the long-term trend, especially given the massive dilution implied by the ADS ratio change. Options data confirms this pessimism, with traders buying deep puts to protect against further ruin rather than betting on a recovery. There is no margin of safety here; the balance sheet is eroding, and the business model appears broken. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.086239 |
| AutoARIMA | 0.087600 |
| AutoETS | 0.087725 |
| AutoTheta | 0.111459 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 0.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.980 |
| Excess Kurtosis | 0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.097 |
| Market Cap | 1,984,777 |
| Forward P/E | -1.21 |
| Beta | -0.55 |
| Previous Name | Kitov Pharma Ltd |
| Website | https://purple-biotech.com |
As of Oct. 10, 2026, 6:19 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Call volume is negligible compared to put activity, with significant open interest concentrated in deep out-of-the-money strikes ($7.50) expiring in early 2027, suggesting a bet on a catastrophic failure or delisting event. Conversely, put buyers are hedging against a drop to $2.50 or lower, indicating a consensus view that the current price is vulnerable to further collapse.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.79769737 |
| Address1 | 4 Oppenheimer Street |
| Address2 | Science Park |
| All Time High | 13,900.0 |
| All Time Low | 1.16 |
| Ask | 1.89 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 24,800 |
| Average Daily Volume3 Month | 1,275,317 |
| Average Volume | 1,275,317 |
| Average Volume10Days | 24,800 |
| Beta | -0.547 |
| Bid | 1.07 |
| Bid Size | 2 |
| Book Value | 12.0 |
| City | Rehovot |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.22 |
| Current Ratio | 3.696 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.2906 |
| Day Low | 1.14 |
| Debt To Equity | 1.097 |
| Display Name | Purple Biotech |
| Dividend Date | 1,597,968,000 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,755,523,740 |
| Earnings Timestamp Start | 1,755,178,140 |
| Ebitda | -7,840,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.599 |
| Enterprise Value | -4,693,105 |
| Eps Current Year | -5.73 |
| Eps Forward | -1.01 |
| Eps Trailing Twelve Months | -47.64 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 509 7196 |
| Fifty Day Average | 1.5605 |
| Fifty Day Average Change | -0.3405 |
| Fifty Day Average Change Percent | -0.21819928 |
| Fifty Two Week Change Percent | -79.76974 |
| Fifty Two Week High | 14.1 |
| Fifty Two Week High Change | -12.88 |
| Fifty Two Week High Change Percent | -0.91347516 |
| Fifty Two Week Low | 1.14 |
| Fifty Two Week Low Change | 0.08000004 |
| Fifty Two Week Low Change Percent | 0.07017548 |
| Fifty Two Week Range | 1.14 - 14.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,448,029,800,000 |
| Float Shares | 1,082,607 |
| Forward Eps | -1.01 |
| Forward P E | -1.2079208 |
| Free Cashflow | -4,903,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 10 |
| Fullday Change | -0.00999999 |
| Fullday Change Percent | -0.81300735 |
| Fullday Price | 1.22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -59,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 1.88929 |
| Held Percent Institutions | 0.10831001 |
| Implied Shares Outstanding | 1,626,867 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,772,409,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel. |
| Long Name | Purple Biotech Ltd |
| Market | us_market |
| Market Cap | 1,984,777 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_20357677 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-16 |
| Net Income To Common | -24,493,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,789,530 |
| Number Of Analyst Opinions | 1 |
| Open | 1.28 |
| Operating Cashflow | -7,758,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 3 933 3121 |
| Prev Name | Kitov Pharma Ltd |
| Previous Close | 1.23 |
| Price Eps Current Year | -0.2129145 |
| Price Hint | 4 |
| Price To Book | 0.10166667 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.424 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.81300735 |
| Regular Market Day High | 1.2906 |
| Regular Market Day Low | 1.14 |
| Regular Market Day Range | 1.14 - 1.2906 |
| Regular Market Open | 1.28 |
| Regular Market Previous Close | 1.23 |
| Regular Market Price | 1.22 |
| Regular Market Time | 1,792,167,582 |
| Regular Market Volume | 13,909 |
| Return On Assets | -0.20306 |
| Return On Equity | -1.11134 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,626,867 |
| Shares Percent Shares Out | 0.0111 |
| Shares Short | 18,115 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 28,119 |
| Short Name | Purple Biotech Ltd. |
| Short Percent Of Float | 0.0111 |
| Short Ratio | 0.01 |
| Source Interval | 15 |
| Symbol | PPBT |
| Target High Price | 17.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 17.0 |
| Total Cash | 6,105,000 |
| Total Cash Per Share | 5.621 |
| Total Debt | 134,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -47.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.33312 |
| Two Hundred Day Average Change | -2.11312 |
| Two Hundred Day Average Change Percent | -0.6339766 |
| Type Disp | Equity |
| Volume | 13,909 |
| Website | https://purple-biotech.com |
| Zip | 7,670,104 |